We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Decompensation Detection Study

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00583089
First Posted: December 31, 2007
Last Update Posted: February 6, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Boston Scientific Corporation
December 20, 2007
December 31, 2007
February 6, 2017
March 2006
March 2008   (Final data collection date for primary outcome measure)
Data collection and analysis. [ Time Frame: End of patient follow up. ]
Same as current
Complete list of historical versions of study NCT00583089 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Decompensation Detection Study
Decompensation Detection Study
To gather data and analyze decompensation events.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Heart failure patients
Heart Failure
Not Provided
  • 1
    Algorithm Test Set
  • 2
    Algorithm Development Set
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
699
March 2008
March 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients implanted with an approved Guidant CRT-D HF device programmed to CRT therapy in VDD or DDD mode.
  • Patients prescribed to the LATITUDE(R) system configured for at least weekly device interrogations and symptoms reporting.
  • Patients willing to use the LATITUDE(R) enabled weight scale.

Exclusion Criteria:

  • Patients that require adaptive rate pacing (rate-responsive modes).
  • Patients that have received routinely scheduled intravenous inotropic therapy as part of their drug regimen within the past 90 days.
  • Both
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00583089
DECODE
No
Not Provided
Not Provided
Boston Scientific Corporation
Boston Scientific Corporation
Not Provided
Principal Investigator: Gregory Ewald, M.D. Washington University School of Medicine
Principal Investigator: F. Roosevelt Gilliam, M.D. Cardiology Associates of Northeast Arkansas
Boston Scientific Corporation
February 2017